JP2018536641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536641A5 JP2018536641A5 JP2018520090A JP2018520090A JP2018536641A5 JP 2018536641 A5 JP2018536641 A5 JP 2018536641A5 JP 2018520090 A JP2018520090 A JP 2018520090A JP 2018520090 A JP2018520090 A JP 2018520090A JP 2018536641 A5 JP2018536641 A5 JP 2018536641A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- formula
- iron
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 34
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 229910052742 iron Inorganic materials 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 206010065973 Iron Overload Diseases 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 238000011260 co-administration Methods 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010022979 Iron excess Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 108091006976 SLC40A1 Proteins 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 201000006288 alpha thalassemia Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 230000010437 erythropoiesis Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 244000000010 microbial pathogen Species 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000035920 Hemoglobin E disease Diseases 0.000 claims 1
- 208000012925 Hemoglobin H disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 208000016286 Iron metabolism disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 206010043390 Thalassaemia alpha Diseases 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 241000607265 Vibrio vulnificus Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 229960001489 deferasirox Drugs 0.000 claims 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims 1
- 229960003266 deferiprone Drugs 0.000 claims 1
- 229960000958 deferoxamine Drugs 0.000 claims 1
- 208000006602 delta-Thalassemia Diseases 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000000925 erythroid effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 102000018511 hepcidin Human genes 0.000 claims 1
- 229940066919 hepcidin Drugs 0.000 claims 1
- 108060003558 hepcidin Proteins 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 235000019195 vitamin supplement Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15191176 | 2015-10-23 | ||
| EP15191176.5 | 2015-10-23 | ||
| EP15191179.9 | 2015-10-23 | ||
| EP15191179 | 2015-10-23 | ||
| PCT/EP2016/075305 WO2017068089A2 (en) | 2015-10-23 | 2016-10-21 | Novel ferroportin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536641A JP2018536641A (ja) | 2018-12-13 |
| JP2018536641A5 true JP2018536641A5 (enExample) | 2019-04-25 |
| JP6810988B2 JP6810988B2 (ja) | 2021-01-13 |
Family
ID=57178421
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520090A Active JP6810988B2 (ja) | 2015-10-23 | 2016-10-21 | 新規なフェロポーチン阻害剤 |
| JP2018520089A Active JP6710754B2 (ja) | 2015-10-23 | 2016-10-21 | 新規なフェロポーチン阻害剤 |
| JP2020091830A Active JP6967112B2 (ja) | 2015-10-23 | 2020-05-27 | 新規なフェロポーチン阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520089A Active JP6710754B2 (ja) | 2015-10-23 | 2016-10-21 | 新規なフェロポーチン阻害剤 |
| JP2020091830A Active JP6967112B2 (ja) | 2015-10-23 | 2020-05-27 | 新規なフェロポーチン阻害剤 |
Country Status (32)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| WO2017068089A2 (en) * | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| CN108314687A (zh) * | 2017-12-27 | 2018-07-24 | 重庆文理学院 | 1,2-二氢苯并[4,5]咪唑并[1,2-a]吡嗪-3（4H）-酮衍生物的合成 |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| ES2934492T3 (es) | 2018-12-13 | 2023-02-22 | Global Blood Therapeutics Inc | Inhibidores de ferroportina y métodos de uso |
| TW202102478A (zh) | 2019-04-01 | 2021-01-16 | 瑞士商威佛（國際）股份有限公司 | 新穎的鐵螯合物 |
| CN114302882A (zh) * | 2019-07-19 | 2022-04-08 | 威佛（国际）股份公司 | 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂 |
| WO2021013772A1 (en) | 2019-07-19 | 2021-01-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
| US20220372099A1 (en) | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| BR112022007616A2 (pt) | 2019-10-22 | 2022-07-12 | Vifor Int Ag | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) |
| AU2021243494B2 (en) * | 2020-03-24 | 2026-07-16 | Vifor (International) Ag | Process for the production of ferroportin inhibitors |
| US11746100B2 (en) * | 2020-04-28 | 2023-09-05 | Global Blood Therapeutics, Inc. | Cycloalkyl pyrimidines as ferroportin inhibitors |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
| WO2022157185A1 (en) | 2021-01-20 | 2022-07-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
| WO2022173818A1 (en) * | 2021-02-09 | 2022-08-18 | University Of Virginia Patent Foundation | Use of biliverdin reductase b inhibitors to allow malaria eradication in patients with g6pd deficiency |
| GEP20267870B (en) * | 2021-03-26 | 2026-03-10 | Chiesi Farm Spa | Tetrahydrothieno pyridine derivatives as ddrs inhibitors |
| TW202304896A (zh) * | 2021-04-22 | 2023-02-01 | 瑞士商威佛（國際）股份有限公司 | 經修飾的膜鐵運輸蛋白(ferroportin)抑制劑 |
| CA3220871A1 (en) | 2021-06-14 | 2022-12-22 | Protagonist Therapeutics, Inc. | Hepcidin mimetics for treatment of hereditary hemochromatosis |
| AR127105A1 (es) * | 2021-09-21 | 2023-12-20 | Vifor Int Ag | Inhibidores de ferroportina n-sustituido |
| WO2024083980A1 (en) | 2022-10-21 | 2024-04-25 | Vifor (International) Ag | Bicyclic ferroportin inhibitors |
| CN115974864B (zh) * | 2022-12-29 | 2025-09-16 | 苏州汉德创宏生化科技有限公司 | 一种2-(3-氮杂环丁基)噻唑盐的合成方法 |
| CN120981247A (zh) | 2023-03-27 | 2025-11-18 | 赛伦斯治疗有限责任公司 | 用于干细胞移植的化合物和组合物 |
| CN121511085A (zh) | 2023-06-26 | 2026-02-10 | 威佛（国际）股份公司 | 用于遗传性血色素沉着病（hh）的治疗的膜铁转运蛋白抑制剂 |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
| WO2026120152A1 (en) | 2024-12-06 | 2026-06-11 | Vifor (International) Ag | Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH479616A (de) * | 1959-12-24 | 1969-10-15 | Ciba Geigy | Verfahren zur Herstellung neuer Methylidenverbindungen |
| GB937878A (en) | 1959-12-24 | 1963-09-25 | Ciba Ltd | N-[5-nitro-(2)-furfurylidene]-pyrazole-carboxylic acid hydrazides and process for their manufacture |
| MY129541A (en) | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| US5922761A (en) | 1996-09-06 | 1999-07-13 | Medinox, Inc. | Methods for in vivo reduction of iron levels and compositions useful therefor |
| PE27799A1 (es) | 1996-12-10 | 1999-03-18 | Novartis Ag | Formulaciones y formas polimorficas de desferrioxamina y su preparacion |
| EP0946587A2 (en) | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| WO2000056724A1 (en) | 1999-03-22 | 2000-09-28 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Oxazole and thiazole combinatorial libraries |
| EP1074254A3 (en) | 1999-07-20 | 2002-09-11 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols with vitamines for treating iron overload |
| EP1072265A1 (en) | 1999-07-20 | 2001-01-31 | MEDIS S.r.l. Medical Infusion Systems | Use of plant polyphenols for treating iron overload |
| NZ524421A (en) * | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| JP2005514330A (ja) * | 2001-09-24 | 2005-05-19 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための置換アミン |
| US20030109548A1 (en) | 2001-11-09 | 2003-06-12 | Royt Paulette W. | Compositions and methods of treating iron excess |
| US6933308B2 (en) | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| DK1656139T3 (da) | 2003-07-21 | 2012-01-30 | Merck Serono Sa | Aryldicarboxamider |
| WO2005014576A1 (ja) | 2003-08-12 | 2005-02-17 | Takeda Pharmaceutical Company Limited | イソキノリノン誘導体、その製造法および用途 |
| DE10356409B4 (de) | 2003-11-28 | 2006-12-28 | Biofrontera Discovery Gmbh | Neues Arzneimittel Oxachelin und Derivate |
| FR2870271B1 (fr) | 2004-05-11 | 2008-03-14 | Bruno Merand | Procede de construction d'une maison en bois et moyens pour la mise en oeuvre du procede. |
| WO2006004841A2 (en) * | 2004-06-29 | 2006-01-12 | The Scripps Research Institute | Galanin agonists |
| WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| EP2954903A1 (en) * | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| US20060252807A1 (en) | 2005-04-22 | 2006-11-09 | Kalypsys, Inc. | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
| US20090118200A1 (en) | 2005-05-23 | 2009-05-07 | Bergman Jeffrey M | Proline bis-amide orexin receptor antagonists |
| KR100970294B1 (ko) | 2005-06-08 | 2010-07-15 | 니뽄 다바코 산교 가부시키가이샤 | 복소환 화합물 |
| EP1928865A1 (en) * | 2005-08-17 | 2008-06-11 | Schering Corporation | Novel high affinity thiophene-based and furan-based kinase ligands |
| CN102659659B (zh) | 2005-11-21 | 2014-07-23 | 盐野义制药株式会社 | 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物 |
| EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN101611007A (zh) | 2006-12-20 | 2009-12-23 | 先灵公司 | 新颖的jnk抑制剂 |
| CL2008000666A1 (es) | 2007-03-07 | 2008-06-13 | Xenon Pharmaceuticals Inc | Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro. |
| AR065785A1 (es) | 2007-03-19 | 2009-07-01 | Xenon Pharmaceuticals Inc | Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro |
| CN101646686A (zh) | 2007-03-20 | 2010-02-10 | 明治制果株式会社 | 铁过剩症的预防或治疗剂 |
| CL2008000793A1 (es) | 2007-03-23 | 2008-05-30 | Xenon Pharmaceuticals Inc | Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro. |
| US8012972B2 (en) * | 2007-03-28 | 2011-09-06 | Santen Pharmaceutical Co., Ltd. | Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure |
| WO2008151288A2 (en) | 2007-06-05 | 2008-12-11 | Xenon Pharmaceuticals Inc. | Aromatic and heteroaromatic compounds useful in treating iron disorders |
| EP2303275A4 (en) | 2008-06-17 | 2012-05-09 | Univ Duke | STANDARD RECEPTOR MODULATORS |
| JP2012500783A (ja) | 2008-08-22 | 2012-01-12 | エヴォテック・アクチエンゲゼルシャフト | 新しいブラジキニンｂ１拮抗薬 |
| PE20110854A1 (es) | 2008-09-26 | 2011-12-23 | Boehringer Ingelheim Int | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 |
| KR101712576B1 (ko) * | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| CA2743723A1 (en) | 2008-11-19 | 2010-05-27 | Pauline C. Ting | Inhibitors of diacylglycerol acyltransferase |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| WO2011029832A1 (de) * | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
| EP2516424B1 (en) * | 2009-12-22 | 2013-12-18 | Syngenta Participations AG | Pyrazole derivatives |
| EP2776411B1 (en) | 2011-11-07 | 2019-06-26 | The University of Queensland | Modulators of c3a receptors |
| BR112014013697A2 (pt) | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| EP2620142A1 (en) * | 2012-01-27 | 2013-07-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Hedgehog signaling pathway involved in energy metabolism |
| AU2013235491A1 (en) | 2012-03-22 | 2014-09-11 | Nanotherapeutics, Inc. | Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles |
| AR091022A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| CN103508957B (zh) | 2012-06-25 | 2017-02-08 | 中国科学院上海药物研究所 | 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途 |
| PL2872157T3 (pl) * | 2012-07-12 | 2020-07-13 | Hangzhou Dac Biotech Co., Ltd | Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi |
| AR097279A1 (es) * | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| WO2015051362A1 (en) | 2013-10-04 | 2015-04-09 | Illinois Institute Of Technology | Multifunctional chelators, complexes, and compositions thereof, and methods of using same |
| WO2015069660A2 (en) | 2013-11-05 | 2015-05-14 | New York Blood Center, Inc. | Methods and compositions for increasing hepcidin expression using modified iron binding/releasing transferrin |
| AU2014352780A1 (en) * | 2013-11-22 | 2016-06-09 | University Of Florida Research Foundation, Inc. | Desferrithiocin analogs and uses thereof |
| WO2016090371A2 (en) * | 2014-12-05 | 2016-06-09 | An2H Discovery Limited | Parkin ligase activation methods and compositions |
| WO2017068089A2 (en) * | 2015-10-23 | 2017-04-27 | Vifor (International) Ag | Novel ferroportin inhibitors |
-
2016
- 2016-10-21 WO PCT/EP2016/075305 patent/WO2017068089A2/en not_active Ceased
- 2016-10-21 BR BR112018007977-4A patent/BR112018007977B1/pt active IP Right Grant
- 2016-10-21 UA UAA201805740A patent/UA123219C2/uk unknown
- 2016-10-21 LT LTEPPCT/EP2016/075306T patent/LT3365339T/lt unknown
- 2016-10-21 FI FIEP16797462.5T patent/FI3365339T3/fi active
- 2016-10-21 JP JP2018520090A patent/JP6810988B2/ja active Active
- 2016-10-21 CN CN202210353448.6A patent/CN114668761B/zh active Active
- 2016-10-21 CA CA3002416A patent/CA3002416C/en active Active
- 2016-10-21 HU HUE16797462A patent/HUE073266T2/hu unknown
- 2016-10-21 US US15/768,025 patent/US10738041B2/en active Active
- 2016-10-21 ES ES16797462T patent/ES3039644T3/es active Active
- 2016-10-21 WO PCT/EP2016/075306 patent/WO2017068090A1/en not_active Ceased
- 2016-10-21 SG SG11201802480YA patent/SG11201802480YA/en unknown
- 2016-10-21 HR HRP20251038TT patent/HRP20251038T1/hr unknown
- 2016-10-21 EP EP16797462.5A patent/EP3365339B1/en active Active
- 2016-10-21 PE PE2018000572A patent/PE20181496A1/es unknown
- 2016-10-21 MY MYPI2018000549A patent/MY198246A/en unknown
- 2016-10-21 RS RS20251013A patent/RS67304B1/sr unknown
- 2016-10-21 MA MA44474A patent/MA44474B1/fr unknown
- 2016-10-21 KR KR1020187011524A patent/KR102352829B1/ko active Active
- 2016-10-21 ES ES16784510T patent/ES3071732T3/es active Active
- 2016-10-21 JP JP2018520089A patent/JP6710754B2/ja active Active
- 2016-10-21 CN CN201680061941.3A patent/CN108290878B/zh active Active
- 2016-10-21 CA CA3002418A patent/CA3002418C/en active Active
- 2016-10-21 US US15/769,148 patent/US10364239B2/en active Active
- 2016-10-21 AU AU2016342310A patent/AU2016342310B2/en active Active
- 2016-10-21 CO CONC2018/0004165A patent/CO2018004165A2/es unknown
- 2016-10-21 DK DK16797462.5T patent/DK3365339T3/da active
- 2016-10-21 MX MX2018004882A patent/MX390514B/es unknown
- 2016-10-21 EP EP16784510.6A patent/EP3364967B1/en active Active
- 2016-10-21 SG SG11201802665VA patent/SG11201802665VA/en unknown
- 2016-10-21 PT PT167974625T patent/PT3365339T/pt unknown
- 2016-10-21 TW TW105134089A patent/TWI722031B/zh active
- 2016-10-21 AU AU2016342309A patent/AU2016342309B2/en active Active
- 2016-10-21 SG SG10202005377VA patent/SG10202005377VA/en unknown
- 2016-10-21 SM SM20250391T patent/SMT202500391T1/it unknown
- 2016-10-21 PL PL16797462.5T patent/PL3365339T3/pl unknown
- 2016-10-21 SI SI201631922T patent/SI3365339T1/sl unknown
- 2016-10-23 JO JOP/2016/0229A patent/JO3780B1/ar active
-
2018
- 2018-03-15 IL IL258159A patent/IL258159B/en unknown
- 2018-03-15 IL IL258158A patent/IL258158B2/en unknown
- 2018-04-06 PH PH12018500769A patent/PH12018500769A1/en unknown
- 2018-04-20 CL CL2018001031A patent/CL2018001031A1/es unknown
- 2018-04-20 MX MX2021015106A patent/MX2021015106A/es unknown
-
2019
- 2019-06-12 US US16/438,596 patent/US11001579B2/en active Active
-
2020
- 2020-05-27 JP JP2020091830A patent/JP6967112B2/ja active Active
- 2020-11-24 AU AU2020277121A patent/AU2020277121C1/en active Active
- 2020-12-03 US US17/110,465 patent/US11066399B2/en active Active
-
2021
- 2021-06-07 US US17/340,692 patent/US20220363675A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535203A5 (enExample) | ||
| IL258158B2 (en) | Compounds for the use of profortin in the prevention and/or treatment of iron metabolism disorders | |
| JP2024521979A5 (enExample) | ||
| JP2021008502A (ja) | ベンゾ複素環化合物および医薬組成物 | |
| AU2014251087B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
| JP2019521988A5 (enExample) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2018535244A (ja) | 関節疾患及び皮膚疾患の治療のためのラパマイシンとメトホルミンの併用 | |
| JP2004531517A5 (enExample) | ||
| CA2443950A1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| US20240287098A1 (en) | Compositions and methods for treating cancer | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| AU2021218740A1 (en) | Mono and combination therapies with ULK1/2 inhibitors | |
| JP2017537886A5 (enExample) | ||
| WO2016014783A1 (en) | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| MX2014002663A (es) | Nuevo esquema de administracion de la n-hidroxi-4-{2-[3-(n,n-dimet ilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida. | |
| WO2020263893A1 (en) | Cannabinoid conjugate molecules | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| EA202191144A1 (ru) | Состав ингибитора bcl-2 на основе циклодекстрина | |
| RU2013112003A (ru) | Противоопухолевые соединения | |
| RU2013136045A (ru) | Ингибиторы каспазы-2 | |
| FR3056108A1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif |